The Latin America, Middle East and Africa Diabetic Retinopathy Market is expected to witness market growth of 14.6% CAGR during the forecast period (2021 2027).
Surgical tools have been majorly improved in terms of precision and accuracy, due to which, the success rate of surgeries and operations is constantly increasing. As a result, the availability of such advanced ophthalmic equipment and systems has enabled medical and treatment operations. Due to this, patients are becoming less hesitant to this treatment alternative. Moreover, an increasing number of people who are becoming aware of the efficiency of the diabetic retinopathy surgery. This factor is considerably propelling the growth of the diabetic retinopathy market all over the region.
The Middle Eastern population is rapidly aging, and because age is a major risk factor for the occurrence of cancer, the frequency, and prevalence of the disease are rising across the region. National, as well as community-based health services, face significant problems as a result of these developments. Most Middle Eastern countries, given their current condition of affairs, require international support to deal with such new problems in their health systems. The training and education of professionals, namely physicians and nurses, in the primary, secondary, and tertiary stages of health services is the focus and priority in dealing with these changing situations. The growing focus of healthcare facilities, as well as government organizations along with research institutes, is expected to majorly drive the demand for the diabetic retinopathy treatment across the region.
The Brazil market dominated the LAMEA Diabetic Retinopathy Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $127.4 Million by 2027. The Argentina market is estimated to witness a CAGR of 15.2% during (2021 - 2027). Additionally, The UAE market is expected to experience a CAGR of 14.3% during (2021 - 2027).
Based on Type, the market is segmented into Proliferative and Diabetic Macular Edema (DME). Based on Treatment Type, the market is segmented into Anti VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (Abbvie, Inc.), Bayer AG, Alimera Sciences, Inc., Novartis AG, Pfizer, Inc., F-Hoffmann-La Roche Ltd., Ampio Pharmaceuticals-us, KOWA CO., LTD., Regeneron Pharmaceuticals, Inc., and Bausch Health Companies, Inc.
Surgical tools have been majorly improved in terms of precision and accuracy, due to which, the success rate of surgeries and operations is constantly increasing. As a result, the availability of such advanced ophthalmic equipment and systems has enabled medical and treatment operations. Due to this, patients are becoming less hesitant to this treatment alternative. Moreover, an increasing number of people who are becoming aware of the efficiency of the diabetic retinopathy surgery. This factor is considerably propelling the growth of the diabetic retinopathy market all over the region.
The Middle Eastern population is rapidly aging, and because age is a major risk factor for the occurrence of cancer, the frequency, and prevalence of the disease are rising across the region. National, as well as community-based health services, face significant problems as a result of these developments. Most Middle Eastern countries, given their current condition of affairs, require international support to deal with such new problems in their health systems. The training and education of professionals, namely physicians and nurses, in the primary, secondary, and tertiary stages of health services is the focus and priority in dealing with these changing situations. The growing focus of healthcare facilities, as well as government organizations along with research institutes, is expected to majorly drive the demand for the diabetic retinopathy treatment across the region.
The Brazil market dominated the LAMEA Diabetic Retinopathy Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $127.4 Million by 2027. The Argentina market is estimated to witness a CAGR of 15.2% during (2021 - 2027). Additionally, The UAE market is expected to experience a CAGR of 14.3% during (2021 - 2027).
Based on Type, the market is segmented into Proliferative and Diabetic Macular Edema (DME). Based on Treatment Type, the market is segmented into Anti VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (Abbvie, Inc.), Bayer AG, Alimera Sciences, Inc., Novartis AG, Pfizer, Inc., F-Hoffmann-La Roche Ltd., Ampio Pharmaceuticals-us, KOWA CO., LTD., Regeneron Pharmaceuticals, Inc., and Bausch Health Companies, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Proliferative
- Diabetic Macular Edema (DME)
By Treatment Type
- Anti VEGF Drug
- Steroid Implants
- Laser Surgeries
- Vitrectomy
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Allergan PLC (Abbvie, Inc.)
- Bayer AG
- Alimera Sciences, Inc.
- Novartis AG
- Pfizer, Inc.
- F-Hoffmann-La Roche Ltd.
- Ampio Pharmaceuticals-us
- KOWA CO., LTD.
- Regeneron Pharmaceuticals, Inc.
- Bausch Health Companies, Inc.
Unique Offerings from the publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Diabetic Retinopathy Market by Type
Chapter 5. LAMEA Diabetic Retinopathy Market by Treatment Type
Chapter 6. LAMEA Diabetic Retinopathy Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Allergan PLC (Abbvie, Inc.)
- Bayer AG
- Alimera Sciences, Inc.
- Novartis AG
- Pfizer, Inc.
- F-Hoffmann-La Roche Ltd.
- Ampio Pharmaceuticals-us
- KOWA CO., LTD.
- Regeneron Pharmaceuticals, Inc.
- Bausch Health Companies, Inc.
Methodology
LOADING...
